Display options
Cite
Tamura A, Yamamoto N, Nino N, et al. Pazopanib maintenance therapy after tandem high-dose chemotherapy for disseminated Ewing sarcoma. Int Cancer Conf J. 2019;8(3):95-100doi: 10.1007/s13691-019-00362-w.
Tamura, A., Yamamoto, N., Nino, N., Ichikawa, T., Nakatani, N., Nakamura, S., Saito, A., Kozaki, A., Kishimoto, K., Ishida, T., Yoshida, M., Akasaka, Y., Hasegawa, D., & Kosaka, Y. (2019). Pazopanib maintenance therapy after tandem high-dose chemotherapy for disseminated Ewing sarcoma. International cancer conference journal, 8(3), 95-100. https://doi.org/10.1007/s13691-019-00362-w
Tamura, Akihiro, et al. "Pazopanib maintenance therapy after tandem high-dose chemotherapy for disseminated Ewing sarcoma." International cancer conference journal vol. 8,3 (2019): 95-100. doi: https://doi.org/10.1007/s13691-019-00362-w
Tamura A, Yamamoto N, Nino N, Ichikawa T, Nakatani N, Nakamura S, Saito A, Kozaki A, Kishimoto K, Ishida T, Yoshida M, Akasaka Y, Hasegawa D, Kosaka Y. Pazopanib maintenance therapy after tandem high-dose chemotherapy for disseminated Ewing sarcoma. Int Cancer Conf J. 2019 Feb 14;8(3):95-100. doi: 10.1007/s13691-019-00362-w. eCollection 2019 Jul. PMID: 31218182; PMCID: PMC6545189.
Copy Download .nbib Format: NLM
Share it on

Int Cancer Conf J. 2019 Feb 14;8(3):95-100. doi: 10.1007/s13691-019-00362-w. eCollection 2019 Jul.

Pazopanib maintenance therapy after tandem high-dose chemotherapy for disseminated Ewing sarcoma.

International cancer conference journal

Akihiro Tamura, Nobuyuki Yamamoto, Nanako Nino, Takayuki Ichikawa, Naoko Nakatani, Sayaka Nakamura, Atsuro Saito, Aiko Kozaki, Kenji Kishimoto, Toshiaki Ishida, Makiko Yoshida, Yoshinobu Akasaka, Daiichiro Hasegawa, Yoshiyuki Kosaka

Affiliations

  1. 1Department of Hematology and Oncology, Kobe Children's Hospital, Minatojima-Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047 Japan.
  2. 2Department of Diagnostic Pathology, Kobe Children's Hospital, Kobe, Japan.
  3. 3Department of Diagnostic Radiology, Kobe Children's Hospital, Kobe, Japan.

PMID: 31218182 PMCID: PMC6545189 DOI: 10.1007/s13691-019-00362-w

Abstract

The dismal prognosis of patients with disseminated Ewing sarcoma necessitates the development of novel treatment strategies. Pazopanib is an oral multi-targeted tyrosine kinase inhibitor that is active against advanced soft tissue sarcoma. However, the clinical activity and feasibility of pazopanib for treating Ewing sarcoma remain poorly understood. Moreover, clinical information on the use of tandem high-dose chemotherapy for Ewing sarcoma is limited. A 14-year-old boy with Ewing sarcoma was transferred to our hospital for treatment. Magnetic resonance imaging, computed tomography scans, and bone scintigraphy revealed multiple lesions in the pubis, ilium, ischium, femur, rib, cranial bone, thoracic vertebrae, sacrum, obturator muscle, adductor magnus muscle, testicular cord, and lungs. Bone scintigraphy after intensive chemotherapies confirmed that multiple abnormal accumulations were still present in the cranial bone and pubis. Subsequently, the patient received tandem high-dose chemotherapy including topotecan, and radiotherapy. Abnormal accumulations have disappeared in bone scintigraphy. Subsequently, pazopanib maintenance therapy was initiated. Despite the presence of innumerable lesions at diagnosis, the patient has been in near-complete remission for the past 1 year with pazopanib administration. This confirms that adding pazopanib maintenance therapy after tandem high-dose chemotherapy is a therapeutic option for cases with disseminated Ewing sarcoma.

Keywords: Disseminated Ewing sarcoma; Pazopanib; Tandem high-dose chemotherapy

Conflict of interest statement

Conflict of interestThe authors have no conflict of interest to disclose. This study was conducted in accordance with the Declaration of Helsinki. Written and oral informed consent for publication was

References

  1. Gynecol Oncol. 2001 Sep;82(3):420-6 - PubMed
  2. Pediatr Blood Cancer. 2006 Jul;47(1):22-9 - PubMed
  3. Pediatr Blood Cancer. 2007 Aug;49(2):196-8 - PubMed
  4. Pediatr Blood Cancer. 2009 Dec;53(6):1029-34 - PubMed
  5. J Clin Oncol. 2010 Jul 10;28(20):3284-91 - PubMed
  6. Bone Marrow Transplant. 2011 Apr;46(4):510-5 - PubMed
  7. Lancet. 2012 May 19;379(9829):1879-86 - PubMed
  8. Int J Urol. 2014 Nov;21(11):1183-4 - PubMed
  9. Acta Oncol. 2015 Jul;54(7):1063-4 - PubMed
  10. Bone Marrow Transplant. 2015 Aug;50(8):1083-8 - PubMed
  11. Rare Tumors. 2015 May 21;7(2):5992 - PubMed
  12. J Clin Oncol. 2015 Sep 20;33(27):3036-46 - PubMed
  13. Oncotarget. 2016 Oct 25;7(43):70959-70968 - PubMed
  14. Intern Med. 2018 Sep 15;57(18):2753-2757 - PubMed
  15. Ann Oncol. 1998 Mar;9(3):275-81 - PubMed

Publication Types